Anti-inflammatory Drugs Market Size, Companies & Industry Research
The global anti-inflammatory drugs market size was valued at USD 120.46 billion in 2023 and is anticipated to reach around USD 272.35 billion by 2033, growing at a CAGR of 8.5% from 2024 to 2033.
The anti-inflammatory drugs market encompasses a wide array of pharmaceuticals designed to alleviate inflammation and its associated symptoms. This market is driven by several factors, including the increasing prevalence of inflammatory conditions such as arthritis, asthma, and inflammatory bowel disease worldwide. The aging population, particularly in developed regions, adds to this demand as older individuals are more susceptible to chronic inflammatory ailments. Furthermore, advancements in drug development technologies have led to the introduction of innovative anti-inflammatory therapies, expanding the market's offerings. Additionally, heightened awareness regarding the importance of early diagnosis and treatment of inflammatory diseases among both patients and healthcare providers is fostering market growth. With a continuous influx of research and development efforts aimed at addressing inflammation-related disorders, the anti-inflammatory drugs market is poised for further expansion in the coming years.
| Report Attribute | Details |
| Market Size in 2024 | USD 130.70 Billion |
| Market Size by 2033 | USD 272.35 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 8.5% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Drug Class, Treatment, Route of Administration, Sales Channel , Distribution channel and Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Merck & Company, Inc., Novartis AG, Amgen, Inc., AstraZeneca plc, Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Biogen Inc., Sun Pharmaceutical Industries Ltd, Mylan, Inc., Aurobindo Pharma Limited, and Dr. Reddy’s Laboratories among others. |
The growth of the anti-inflammatory drugs market is primarily driven by several factors. Firstly, the rising incidence of inflammatory diseases such as arthritis, asthma, and inflammatory bowel disease among the global population is fueling the demand for these medications. Additionally, the aging population worldwide is prone to developing chronic inflammatory conditions, further contributing to market expansion. Moreover, advancements in drug development technologies and the introduction of novel anti-inflammatory therapies are propelling market growth. Furthermore, the increasing awareness about the benefits of early diagnosis and treatment of inflammatory diseases is encouraging patients to seek medical intervention, thereby boosting the demand for anti-inflammatory drugs. Overall, these factors combined are driving the growth of the anti-inflammatory drugs market on a global scale.
The COVID-19 pandemic impacted slightly negative on the anti-inflammatory drugs market gains. During the initial phase of the COVID-19 pandemic, various anti-inflammatory drugs, including nonsteroidal anti-inflammatory drugs (NSAIDs), were used to manage fever, pain and inflammation associated with COVID-19 symptoms. However, concerns were raised regarding the potential negative effects of NSAIDs on COVID-19 outcomes. These concerns stemmed from the fact that NSAIDs may potentially worsen the immune response and increase the risk of complications.
Drivers:
According to the World Health Organization, the increasing geriatric population is around 1 billion people aged 60 and above. The number is expected to reach 2 billion or double by 2050. The tendons of the body become less elastic with age and are prone to injury. Furthermore, moderate chronic pain at an early age becomes severe chronic pain if not treated properly. As the bone loses density and mass, it becomes more vulnerable to injury. The systemic inflammation progresses with age, and the pain is more severe. The pain also persists over a long duration. The prevalence of diabetes is also a significant contributing factor to the increased inflammation in elderlies. The increasing number of cancer patients also contributes to the growing demand for anti-inflammatory drugs. Therefore, the rising geriatric population will drive the global anti-inflammatory drugs market. The increasing accessibility to medication is a complementary development benefiting the market.
Restraints:
Increasing awareness about the potential side effects of the drugs – Every drug has several possible side effects that vary in severity. The widespread use of anti-inflammatory drugs has prompted scientists globally to understand their potential side effects on patients. The increasing research has presented extensive evidence connecting NSAIDs to the rising risk of cardiovascular conditions. The conditions can be heart attacks, heart failure, heart stroke, and atrial fibrillation. The increasing awareness about the potential side effects of anti-inflammatory drugs will reduce the demand for the drugs in the market, given the rising concerns about their consumption. Therefore, this could limit the growth of the market.
Opportunities:
Research and development in the market – The increasing awareness about anti-inflammatory drugs has increased their demand. The major players in the market are perpetually involved in the research and development of new drugs to exploit the massive consumer market of anti-inflammatory drugs. The extensive portfolio and their easy accessibility are also aiding the market's growth. For instance, the development of anti-inflammatory biologics that have lesser side effects on the body and are more effective in treating pain is ushering in a new market development era. The comprehensive approval mechanisms have been streamlined to fast-track drug approvals, encourage innovation in the market and improve industry compliance. The standardized regulations of the government are also facilitating better product innovations in the market. Therefore, enhanced research and development will offer lucrative opportunities for the market.
Challenges:
Concerns about patent expiry - The pharmaceutical giants spend millions on research and development of new drugs, therapies, and treatments that could potentially cure a condition or disease. A company's extensive research and development are only carried out when they are guaranteed an exclusive right to manufacture, produce and distribute its drug in the public domain. The patents awarded by regulators guarantee that the pharmaceutical giants can reap the benefits of their discovery and recover the money they put into developing the drugs and profits. However, the patents are awarded for a specific time, and the expiration of a patent opens up the opportunity for other market players to reverse engineer and sell the same drug without any significant expenditure. Poor patent laws and inadequate implementation discourage innovation and could challenge the market's growth.
Increasing prevalence of autoimmune disease and respiratory conditions have significantly created the demand for anti-inflammatory drugs. Autoimmune disease such as rheumatoid arthritis, lupus, and multiple sclerosis are on the rise globally. Various factors such as genetic predisposition, exposure to certain chemicals, hormonal imbalances, smoking, sedentary lifestyle significantly contributes to the autoimmune disease and respiratory conditions.
Therefore, adoption of anti-inflammatory drugs will help suppress the excessive immune response, reduce inflammation and alleviate symptoms. Similarly in respiratory conditions such as asthma and COPD, anti-inflammatory drugs help decrease airway inflammation, bronchoconstriction and mucus production, resulting in improved lung function and symptom control.
By drug class, the anti-inflammatory drugs market is classified into anti-inflammatory biologics, nonsteroidal anti-inflammatory drugs (NSAIDS), corticosteroids and other drug class. Anti-inflammatory biologics segment accounted for 45.7% of the market share in 2023. Anti-inflammatory biologics target specific inflammatory pathways and aids in effectively reducing the inflammation and provide significant relief from symptoms such as pain, swelling, and joint stiffness. They are beneficial in autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease as compared to traditional treatments.
Based on treatment, the anti-inflammatory drugs market is segmented into arthritis, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), multiple sclerosis and other treatments. The arthritis segment is expected to register over USD 73.5 billion by 2033. Anti-inflammatory drugs help reduce inflammation, relieve pain and improve joint function caused due to arthritis. These drugs provide symptomatic relief and slow down the disease progression by effectively managing arthritis symptoms that allows patients to perform daily activities with greater ease and functionality.
By route of administration, the anti-inflammatory drugs market is segmented into oral, breast cancer, topical, injection and intranasal. The oral segment is expected to grow at 9.3% by 2033. Oral route of administration includes medication in the form of tablets, capsules and liquids. This route of administration is convenient, easily accessible and can be self-administered at home. Also, the oral form of anti-inflammatory drugs are composed in appropriate proportion that enables the individual to intake the correct proportion of dosage. Furthermore, oral anti-inflammatory drugs have a well-established formulation and manufacturing process, contributing to their widespread availability and affordability.
The distribution channel segment is divided into hospital pharmacies, online pharmacies, retail pharmacies, and others. The retail pharmacies segment dominated the market with a market share of around 56% in 2023. The increasing number of supermarket pharmacies facilitates the expansion of the industry. Anti-inflammatory drugs mostly don't require a prescription and are widely available as over-the-counter drugs in pharmacies, which increases the demand for retail pharmacies. Retail pharmacies' accessibility has a big impact on the segment's growth.
The sales channel segment of anti-inflammatory drugs market is divided into prescription and over the counter (OTC) drugs. Prescription segment accounted for USD 56.14 billion market revenue in 2023. The prescription-based anti-inflammatory drugs are appropriately prescribed, monitored and used under medical supervision. This helps to optimize patient safety and ensures that the medications are used effectively for the intended purposes in appropriate dosage level. Additionally, the prescription sales model provides opportunities for pharmaceutical companies to collaborate with healthcare providers and enables strong establishment with healthcare institutions and pharmacies.
North America anti-inflammatory drugs market accounted for over 41.11% market share in 2023. The increasing prevalence of inflammatory diseases such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), psoriasis among others is expected to boost the industry development. Also, growing geriatric population, sedentary lifestyles, and increasing awareness of disease management is expected to further accelerate the demand for anti-inflammatory drugs in the North America region. The advanced healthcare infrastructure, presence of key players and strong R&D facilities have contributed to the significant adoption and commercial success of anti-inflammatory drugs.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Anti-inflammatory Drugs market.
By Drug Class
By Treatment
By Route of Administration
By Distribution Channel
By Sales Channel
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers